000096028 001__ 96028
000096028 005__ 20201029165924.0
000096028 0247_ $$2doi$$a10.1089/dia.2019.2525.abstracts
000096028 0248_ $$2sideral$$a111587
000096028 037__ $$aART-2019-111587
000096028 041__ $$aeng
000096028 100__ $$aLou, G.M.
000096028 245__ $$aExperience of CGM (Continuous Glucose Monitoring) for children and adolescents in a paedriatric diabetes unit
000096028 260__ $$c2019
000096028 5060_ $$aAccess copy available to the general public$$fUnrestricted
000096028 5203_ $$aAbstract [ATTD19-0011]
Objective: Estimate the use of CGM in a Pediatric Diabetes Unit from a Spanish region. To find out differences between the different CGM systems (included flash type or intermittent) and according to the type of treatment. To analyze the metabolic control, frequency of mild and severe hypoglycaemia among the same patients before and after using CGM and to compare patients with and without CGM.
Methods: Data are collected from September to December 2017, from patients whose diagnosis was between 2003 and 2017. Patients are grouped in age groups (<5; 6–10;> 10) and demographic, metabolic control and treatment variables are collected.
Results: 120 patients collaborated, implying a response of 80%.70% use MDI, of which 48% use CGM, being 89% in the case of patients using CSII. In older than 10 years there is a predilection for intermittent measurement systems, unlike those under 5 years prefer continuous measurement. The use of CGM significantly reduces HbA1c compared to those who do not use them and significantly reduces the number of mild hypoglycaemia, with the disappearance of severe hypoglycaemia in 6 months. 43% of patients reduce the number of glycemias/day significantly after 6 months of use. CGM decreases almost a 5% the HbAc1 value and a 19% the Coefficient of Variation.
Conclusion: There exists an improvement in the metabolic control and the glycemic variability of using CGM. Hypoglycemia is diminished by GCM, to a greater extent by the Integrated sensor-augmented pump system. Adolescents prefer to use intermittent measurement systems, reducing the number of glycemia/d.
000096028 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000096028 590__ $$a4.392$$b2019
000096028 591__ $$aENDOCRINOLOGY & METABOLISM$$b30 / 143 = 0.21$$c2019$$dQ1$$eT1
000096028 592__ $$a1.819$$b2019
000096028 593__ $$aEndocrinology$$c2019$$dQ1
000096028 593__ $$aMedicine (miscellaneous)$$c2019$$dQ1
000096028 593__ $$aMedical Laboratory Technology$$c2019$$dQ1
000096028 593__ $$aEndocrinology, Diabetes and Metabolism$$c2019$$dQ1
000096028 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion
000096028 700__ $$aBarbed, S.
000096028 700__ $$0(orcid)0000-0001-5858-4975$$aLarramona, G.$$uUniversidad de Zaragoza
000096028 700__ $$aFerrer, M.
000096028 700__ $$0(orcid)0000-0002-9253-6448$$aMontaner, T.$$uUniversidad de Zaragoza
000096028 7102_ $$14000$$2415$$aUniversidad de Zaragoza$$bDpto. Análisis Económico$$cÁrea Fund. Análisis Económico
000096028 7102_ $$14011$$2095$$aUniversidad de Zaragoza$$bDpto. Direc.Mark.Inves.Mercad.$$cÁrea Comerci.Investig.Mercados
000096028 773__ $$g21, S1 (2019), A90-A91$$pDiabetes Technology & Therapeutics$$tDiabetes Technology & Therapeutics$$x1520-9156
000096028 85641 $$uhttps://www.liebertpub.com/doi/pdf/10.1089/dia.2019.2525.abstracts$$zTexto completo de la revista
000096028 8564_ $$s53342$$uhttps://zaguan.unizar.es/record/96028/files/texto_completo.pdf$$yVersión publicada
000096028 8564_ $$s22292$$uhttps://zaguan.unizar.es/record/96028/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000096028 909CO $$ooai:zaguan.unizar.es:96028$$particulos$$pdriver
000096028 951__ $$a2020-10-29-14:06:48
000096028 980__ $$aARTICLE